ProfileGDS4814 / ILMN_2249720
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 10% 21% 18% 7% 10% 13% 16% 20% 17% 7% 20% 16% 1% 26% 10% 11% 9% 9% 25% 19% 2% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)41.125710
GSM780708Untreated after 4 days (C2_1)43.737321
GSM780709Untreated after 4 days (C3_1)43.07418
GSM780719Untreated after 4 days (C1_2)40.18667
GSM780720Untreated after 4 days (C2_2)41.201610
GSM780721Untreated after 4 days (C3_2)41.882813
GSM780710Trastuzumab treated after 4 days (T1_1)42.785716
GSM780711Trastuzumab treated after 4 days (T2_1)43.467220
GSM780712Trastuzumab treated after 4 days (T3_1)42.924117
GSM780722Trastuzumab treated after 4 days (T1_2)40.11937
GSM780723Trastuzumab treated after 4 days (T2_2)43.485120
GSM780724Trastuzumab treated after 4 days (T3_2)42.705616
GSM780713Pertuzumab treated after 4 days (P1_1)33.80651
GSM780714Pertuzumab treated after 4 days (P2_1)44.814826
GSM780715Pertuzumab treated after 4 days (P3_1)41.20210
GSM780725Pertuzumab treated after 4 days (P1_2)41.549911
GSM780726Pertuzumab treated after 4 days (P2_2)40.76669
GSM780727Pertuzumab treated after 4 days (P3_2)40.78239
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)44.615425
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)43.397219
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)37.5682
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)40.78739
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)40.72819